Krystal Biotech, Inc.
KRYS
$345.70
-$2.40-0.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 241.46M | 225.03M | 204.83M | 198.91M | 146.73M |
| Total Depreciation and Amortization | 2.37M | 2.54M | 2.45M | 2.14M | 2.16M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.18M | 30.51M | 30.00M | 26.73M | 52.02M |
| Change in Net Operating Assets | -2.67M | -7.80M | -36.42M | -51.58M | -5.51M |
| Cash from Operations | 272.34M | 250.28M | 200.87M | 176.20M | 195.40M |
| Capital Expenditure | -14.56M | -12.90M | -11.95M | -10.61M | -9.96M |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 435.00K | 435.00K | 435.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -203.73M | -54.34M | -46.90M | -143.18M | -173.88M |
| Cash from Investing | -218.29M | -67.23M | -58.42M | -153.36M | -183.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 41.07M | 27.70M | 22.66M | 9.40M | 9.05M |
| Repurchase of Common Stock | -17.10M | -16.99M | -13.96M | -13.93M | -13.93M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 23.97M | 10.71M | 8.71M | -4.53M | -4.88M |
| Foreign Exchange rate Adjustments | -4.11M | -1.22M | 286.00K | 329.00K | 922.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.91M | 192.54M | 151.44M | 18.64M | 8.04M |